(Q46899549)

26 December 2017

title

Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery (English)

1 reference

26 December 2017

0 references

1 reference

1 reference

1 reference

Jean C Sung

1

1 reference

26 December 2017

Danielle J Padilla

2

1 reference

26 December 2017

Lucila Garcia-Contreras

3

1 reference

26 December 2017

Jarod L Verberkmoes

4

1 reference

26 December 2017

David Durbin

5

1 reference

26 December 2017

Charles A Peloquin

6

1 reference

26 December 2017

Katharina J Elbert

7

1 reference

26 December 2017

Anthony J Hickey

8

1 reference

26 December 2017

David A Edwards

9

1 reference

26 December 2017

publication date

30 April 2009

1 reference

26 December 2017

published in

Pharmaceutical Research

1 reference

26 December 2017

volume

26

1 reference

26 December 2017

issue

8

1 reference

26 December 2017

page(s)

1847-1855

1 reference

26 December 2017

Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery

cites work

1 reference

12 December 2020

Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions

1 reference

12 December 2020

Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization

1 reference

12 December 2020

Molecular weight distribution changes during degradation and release of PLGA nanoparticles containing epirubicin HCl.

1 reference

12 December 2020

The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy

1 reference

12 December 2020

Slow release formulations of inhaled rifampin

1 reference

12 December 2020

Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs

1 reference

12 December 2020

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

1 reference

12 December 2020

Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features

1 reference

12 December 2020

A review of the technical aspects of drug nebulization

1 reference

12 December 2020

The lungs as a portal of entry for systemic drug delivery

1 reference

12 December 2020

Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis

1 reference

12 December 2020

Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis

1 reference

12 December 2020

Microencapsulated chitosan nanoparticles for lung protein delivery

1 reference

12 December 2020

Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung

1 reference

12 December 2020

Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect

1 reference

12 December 2020

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

1 reference

12 December 2020

Mycobacterium tuberculosis: here today, and here tomorrow

1 reference

12 December 2020

Airways delivery of rifampicin microparticles for the treatment of tuberculosis

1 reference

12 December 2020

A practical approach to the use of nanoparticles for vaccine delivery

1 reference

12 December 2020

Effect of amino acids on the dispersion of disodium cromoglycate powders

1 reference

12 December 2020

The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis

1 reference

12 December 2020

Trojan particles: large porous carriers of nanoparticles for drug delivery.

1 reference

12 December 2020

Nanoparticles for drug delivery to the lungs

1 reference

12 December 2020

Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959.

1 reference

12 December 2020

Single dose and multiple dose studies of itraconazole nanoparticles.

1 reference

12 December 2020

Large porous particles for pulmonary drug delivery

1 reference

12 December 2020

Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles

1 reference

12 December 2020

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin

1 reference

12 December 2020

Suitability of rifampicin for intermittent administration in the treatment of tuberculosis

1 reference

12 December 2020

Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis

1 reference

12 December 2020

Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles

1 reference

12 December 2020

Direct lung delivery of para-aminosalicylic acid by aerosol particles

1 reference

12 December 2020

Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.

1 reference

12 December 2020

A literature review of the problems of delayed presentation for treatment and non-completion of treatment for tuberculosis in less developed countries and ways of addressing these problems using particular implementations of the DOTS strategy

1 reference

12 December 2020

Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model

1 reference

12 December 2020

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model

1 reference

12 December 2020

10.1007/S11095-009-9894-2

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

19407933

1 reference

26 December 2017